Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
$238.00 Multi-Receptor Metabolic Peptide Blend for Research Technical Overview This co-formulated blend pairs Retatrutide, a synthetic peptide studied as a triple agonist across the GIP, GLP-1, and glucagon receptor families, with Cagrilintide, a long-acting amylin analogue
Compound Profile Scientific & Efficacy Data C 194 H 312 N 54 O 59 S 2 Molecular Formula 4409 g/mol Molecular Weight 159-195 hours (~7-8 days) Half-Life ~100% (subcutaneous) Bioavailability 1415456-99-3 CAS # 171397054 PubChem ID Developed By 2021 Thomas Kruse Novo Nordisk Primary Benefits Exceptional appetite suppression through dual amylin and calcitonin receptor activation, creating powerful and sustained satiety signals Impressive 10-15% weight loss alone, or 20%+ when combined with semaglutide in the CagriSema combination Uniquely designed to complement GLP-1 medications through an independent mechanism, dramatically enhancing results when combined Amino Acid Sequence Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (acylated with C18 diacid via gamma-Glu linker) Dosing How much do I take
2003;93(3 Pt 2):1022-1024
Altered ultrastructure of mitochondrial membranes is strongly associated with unexplained asthenozoospermia
In parallel, animals in the untreated CIM group demonstrated a clear state of oxidative stress, reflected by reduced SOD, CAT, and GPx4 and increased MDA levels, which agrees with prior 5-FU mucositis models in mice and rats (Rtibi et al
US$ 21.00
US$ 20.32
US$ 24.50
US$ 29.70
US$ 20.45
US$ 28.17
US$ 24.40
